Vision & Mission

Combining cancer vaccines
and T-cell therapies

ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).

Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

About us

Latest News

  • Published On: November 8th, 2022

    Paola Bonaventura, project leader at ErVaccine Technologies,  has been giving a talk  entitled “Human Endogenous Retrovirus (HERVs) Represent a Source of Shared Tumour Epitopes Inducing High Avidity Cytotoxic T cells […]

  • Published On: September 22nd, 2022

    Stéphane Depil, founder and CEO of ErVaccine Technologies,  will give a talk  entitled “Human Endogenous Retrovirus  Represent a Source of Shared Tumor Epitopes Inducing High-Avidity Cytotoxic T cells for Cancer […]

  • Published On: September 22nd, 2022

    ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of their research collaborative project (PRCE) grant proposal by […]

Latest Publications & Abstracts

  • Categories: Publications & abstractsPublished On: June 28th, 2022
  • Categories: Publications & abstractsPublished On: June 16th, 2022
  • Categories: Publications & abstractsPublished On: January 27th, 2022
  • Categories: Publications & abstractsPublished On: December 17th, 2021